Immunotherapy in cervix cancer

Laura Attademo; Valentina Tuninetti; Carmela Pisano; Sabrina Chiara Cecere; Marilena Di Napoli; Rosa Tambaro; Giorgio Valabrega; Lucia Musacchio; Sergio Venanzio Setola; Patrizia Piccirillo; Daniela Califano; Anna Spina; Simona Losito; Stefano Greggi; Sandro Pignata

doi:10.1016/j.ctrv.2020.102088

Immunotherapy in cervix cancer

Laura Attademo, Valentina Tuninetti, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Rosa Tambaro, Giorgio Valabrega, Lucia Musacchio, Sergio Venanzio Setola, Patrizia Piccirillo, Daniela Califano, Anna Spina, Simona Losito, Stefano Greggi, Sandro Pignata

Istituto Oncologico Candiolo

Research output: Contribution to journal › Review article › peer-review

Abstract

The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.

Original language	English
Pages (from-to)	102088
Journal	Cancer Treat. Rev.
Volume	90
DOIs	https://doi.org/10.1016/j.ctrv.2020.102088
Publication status	Published - Nov 2020

Keywords

Antineoplastic Agents, Immunological/therapeutic use
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Female
Humans
Neoplasm Staging
Randomized Controlled Trials as Topic
Uterine Cervical Neoplasms/drug therapy

Access to Document

10.1016/j.ctrv.2020.102088

Fingerprint Dive into the research topics of 'Immunotherapy in cervix cancer'. Together they form a unique fingerprint.

Cite this

Immunotherapy in cervix cancer. / Attademo, Laura; Tuninetti, Valentina; Pisano, Carmela; Cecere, Sabrina Chiara; Di Napoli, Marilena; Tambaro, Rosa; Valabrega, Giorgio; Musacchio, Lucia; Setola, Sergio Venanzio; Piccirillo, Patrizia; Califano, Daniela; Spina, Anna; Losito, Simona; Greggi, Stefano; Pignata, Sandro.

In: Cancer Treat. Rev., Vol. 90, 11.2020, p. 102088.

Research output: Contribution to journal › Review article › peer-review

Attademo, Laura ; Tuninetti, Valentina ; Pisano, Carmela ; Cecere, Sabrina Chiara ; Di Napoli, Marilena ; Tambaro, Rosa ; Valabrega, Giorgio ; Musacchio, Lucia ; Setola, Sergio Venanzio ; Piccirillo, Patrizia ; Califano, Daniela ; Spina, Anna ; Losito, Simona ; Greggi, Stefano ; Pignata, Sandro. / Immunotherapy in cervix cancer. In: Cancer Treat. Rev. 2020 ; Vol. 90. pp. 102088.

@article{eefb74643ede49ed8f3b8def87393394,

title = "Immunotherapy in cervix cancer",

abstract = "The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.",

keywords = "Antineoplastic Agents, Immunological/therapeutic use, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Female, Humans, Neoplasm Staging, Randomized Controlled Trials as Topic, Uterine Cervical Neoplasms/drug therapy",

author = "Laura Attademo and Valentina Tuninetti and Carmela Pisano and Cecere, {Sabrina Chiara} and {Di Napoli}, Marilena and Rosa Tambaro and Giorgio Valabrega and Lucia Musacchio and Setola, {Sergio Venanzio} and Patrizia Piccirillo and Daniela Califano and Anna Spina and Simona Losito and Stefano Greggi and Sandro Pignata",

note = "Copyright {\textcopyright} 2020. Published by Elsevier Ltd.",

year = "2020",

month = nov,

doi = "10.1016/j.ctrv.2020.102088",

language = "English",

volume = "90",

pages = "102088",

journal = "Cancer Treat. Rev.",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Immunotherapy in cervix cancer

AU - Attademo, Laura

AU - Tuninetti, Valentina

AU - Pisano, Carmela

AU - Cecere, Sabrina Chiara

AU - Di Napoli, Marilena

AU - Tambaro, Rosa

AU - Valabrega, Giorgio

AU - Musacchio, Lucia

AU - Setola, Sergio Venanzio

AU - Piccirillo, Patrizia

AU - Califano, Daniela

AU - Spina, Anna

AU - Losito, Simona

AU - Greggi, Stefano

AU - Pignata, Sandro

PY - 2020/11

Y1 - 2020/11

N2 - The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.

AB - The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.

KW - Antineoplastic Agents, Immunological/therapeutic use

KW - Clinical Trials, Phase II as Topic

KW - Clinical Trials, Phase III as Topic

KW - Female

KW - Humans

KW - Neoplasm Staging

KW - Randomized Controlled Trials as Topic

KW - Uterine Cervical Neoplasms/drug therapy

U2 - 10.1016/j.ctrv.2020.102088

DO - 10.1016/j.ctrv.2020.102088

M3 - Review article

C2 - 32827839

VL - 90

SP - 102088

JO - Cancer Treat. Rev.

JF - Cancer Treat. Rev.

SN - 0305-7372

ER -